Patients' perceptions, attitudes, and experiences about the management of mild-to-moderate ulcerative colitis

被引:14
|
作者
Casellas, Francesc [1 ]
Vicens, Daniel Ginard [2 ]
Riestra Menendez, Sabino [3 ]
Alfaro Oliver, Noelia [4 ]
机构
[1] Hosp Univ Vall dHebron, Ciberehd, Crohn Colitis Care Unit, Barcelona 08035, Spain
[2] Hosp Univ Son Espases, Dept Gastroenterol, Palma de Mallorca 07120, Islas Baleares, Spain
[3] Hosp Univ Cent Asturias, Dept Gastroenterol, Oviedo 33006, Asturias, Spain
[4] Adv Res Tech Hlth Serv TAISS, Madrid 28034, Spain
来源
JOURNAL OF CROHNS & COLITIS | 2014年 / 8卷 / 09期
关键词
Ulcerative colitis; Management of the disease; Treatment of the disease; Quality of life; Patient satisfaction; INFLAMMATORY-BOWEL-DISEASE; HEALTH-CARE; SATISFACTION; PERSPECTIVE; COPENHAGEN;
D O I
10.1016/j.crohns.2014.02.013
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective: To establish the perceptions, attitudes, experiences, and satisfaction with clinical management of ulcerative colitis (UC) patients, particularly in aspects related to treatment. Methods: A qualitative, descriptive, exploratory study. A discussion group was performed in patients who were in remission according to the criteria of the Mayo index, who had never taken biologics or corticosteroids in the past year. They were selected by: course (mild/moderate), time since onset (under 5 years/5 to 9 years/10 years or more), follow-up area (primary care [PC]-hospital/PC-specialist care/hospital), treatment (yes/no), UC care unit (yes/no), belongs to patient associations (yes/no) and sex. A descriptive-interpretative content analysis was performed to detect emerging categories, providing them with an explanatory framework. Results: Diagnostic delay was detected due to lack of clinical suspicion from PC and delayed diagnostic tests. For follow-up, patients prefer care on demand, channeled through remote care, which helps to resolve questions, problems with treatment, or when a relapse occurs, minimizing visits to the hospital. They demand more information, both about UC and treatment. The expectations about treatments are limited, so they mainly requested efficacy and safety. Conclusion: The results suggest the importance of developing strategies to facilitate care on demand and remote care, and to investigate on effective and safe treatments to minimize the detriment to quality of life of patients. These strategies should guarantee fast care and, together with safe and effective treatments, optimize the management of UC patients. (C) 2014 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1097 / 1107
页数:11
相关论文
共 50 条
  • [31] Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild-to-Moderate Ulcerative Colitis
    Cross, Raymond K.
    INFLAMMATORY BOWEL DISEASES, 2017, 23 (10) : 1689 - 1701
  • [32] Effect of Extended MMX Mesalamine Therapy for Acute, Mild-to-Moderate Ulcerative Colitis
    Kamm, Michael A.
    Lichtenstein, Gary R.
    Sandborn, William J.
    Schreiber, Stefan
    Lees, Kirstin
    Barrett, Karen
    Joseph, Raymond
    INFLAMMATORY BOWEL DISEASES, 2009, 15 (01) : 1 - 8
  • [33] Recommendations for the optimal use of mesalazine in the management of patients with mild to moderate ulcerative colitis
    Akbar, Ayesha
    Arnott, Ian
    Kennedy, Nicholas A.
    Nolan, Jonathan
    Peake, Simon
    Whiteoak, Simon R.
    Probert, Chris
    Fraser, Aileen
    Cheshire, Alex
    Lewis, Allyson
    Sugrue, Kathleen
    Laird, Susan
    Scott, Glyn
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2021, 82 (10)
  • [34] Segmental Endoscopic Evaluation of Combined Oral and Topical Mesalazine (Pentasa®) in Patients With Mild-to-Moderate Ulcerative Colitis
    Suzuki, Yasuo
    Inou, Soetsu
    Uchiyama, Kan
    Kato, Masahisa
    Matsuo, Keigo
    Nakagawa, Tomoo
    Kato, Kazuki
    Kishikawa, Hiroshi
    Kimura, Norio
    GASTROENTEROLOGY, 2012, 142 (05) : S655 - S655
  • [35] Satisfaction with therapy among patients treated with MMX™ mesalamine for maintenance of remission in patients with mild-to-moderate ulcerative colitis
    Sandborn, W.
    Lichtenstein, G.
    Kamm, M.
    Barrett, K.
    Joseph, R.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (01) : S24 - S24
  • [36] Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial
    Lang, Alon
    Salomon, Nir
    Wu, Justin C. Y.
    Kopylov, Uri
    Lahat, Adi
    Har-Noy, Ofir
    Ching, Jessica Y. L.
    Cheong, Pui Kuan
    Avidan, Benjamin
    Gamus, Dorit
    Kaimakliotis, Ioannis
    Eliakim, Rami
    Ng, Siew C.
    Ben-Horin, Shomron
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (08) : 1444 - +
  • [37] Multi-Matrix System (MMX®) mesalamine for the treatment of mild-to-moderate ulcerative colitis
    Horst, Sara N.
    Kane, Sunanda
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (15) : 2225 - 2232
  • [38] Mild-to-moderate ulcerative colitis: Your role in patient compliance and health care costs
    Tindall, William N.
    Boltri, John M.
    Wilhelm, Sheila M.
    JOURNAL OF MANAGED CARE PHARMACY, 2007, 13 (07): : S2 - S12
  • [39] MMX™ mesalamine is effective for the maintenance of remission of mild-to-moderate ulcerative colitis irrespective of patients' previous relapse history
    Sandborn, William J.
    Karlstadt, Robyn
    Barrett, Karen
    Joseph, Raymond E.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 : S461 - S462
  • [40] MMX® mesalamine treatment for patients with mild-to-moderate ulcerative colitis: improvement in health-related quality of life
    Kane, S.
    Yen, L.
    Yarlas, A.
    Karlstadt, R.
    Solomon, D.
    Hodgkins, P.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2010, 25 : A92 - A92